MedDataX Logo

A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)

NCT ID: NCT00127179

Last Updated: 2024-08-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

600 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-01-01

Study Completion Date

2005-07-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with benign prostatic hyperplasia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)

NCT01534351

Benign Prostatic Hyperplasia
TERMINATED PHASE3

Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)

NCT03297398

Benign Prostatic Hyperplasia
TERMINATED PHASE2

Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects

NCT00368979

Prostatic Hyperplasia
COMPLETED PHASE3

A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms

NCT01139762

Benign Prostatic Hyperplasia Enlarged Prostate
COMPLETED PHASE3

On Label, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Finasteride in Patients Undergoing Transurethral Resection of the Prostate (TURP)

NCT00564460

Benign Prostatic Hyperplasia
WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Benign Prostatic Hyperplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK0906, finasteride / Duration of Treatment: 48 weeks

Intervention Type DRUG

Comparator: placebo / Duration of Treatment: 48 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with benign prostatic hyperplasia

Exclusion Criteria

* Patients who are suspected to be suffering from prostatic cancer
Minimum Eligible Age

50 Years

Maximum Eligible Age

79 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Organon and Co

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MK0906-140

Identifier Type: -

Identifier Source: secondary_id

2005_042

Identifier Type: -

Identifier Source: secondary_id

0906-140

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Trial of PROSCAR (Finasteride) Versus Placebo in Men With an Initial Negative Prostate Biopsy
NCT00542243 COMPLETED PHASE3
Prospective Sexual Function Study for BPH Subjects
NCT01777269 COMPLETED PHASE4
New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia
NCT06944145 RECRUITING PHASE2
Α Prospective Observational Study for the Evaluation of Disease Control and Quality of Life in Patients With Benign PROStatic hyPERplasia Under Fixed Dose combΙnaTion Treatment With Dutasteride and Tamsulosin . PROSPERITY Group of Studies (I&II)
NCT04831476 COMPLETED
Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)
NCT00527605 COMPLETED PHASE3
Dutasteride for Improving Peri-Operative and Long-Term Outcomes of Photoselective Vaporization of the Prostate (DOP)
NCT00274417 UNKNOWN NA
Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia
NCT00701779 COMPLETED PHASE4
Extension Study of GI198745 to Treat Benign Prostatic Hyperplasia
NCT00969072 COMPLETED PHASE2
A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart
NCT00690950 UNKNOWN PHASE4
Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00375765 COMPLETED PHASE4
High Risk Prostate Cancer Prevention Study
NCT01174953 COMPLETED NA
Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia
NCT04947631 COMPLETED PHASE3
Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment
NCT00090103 COMPLETED PHASE3
Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) Levels
NCT00062790 COMPLETED PHASE4
This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood Samples
NCT01957189 COMPLETED PHASE1
A Study in Benign Prostatic Hyperplasia
NCT01152190 COMPLETED PHASE3
A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry.
NCT01254071 COMPLETED PHASE1
A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance
NCT02146937 WITHDRAWN PHASE2
Minimally Invasive Surgical Therapy for BPH
NCT00064649 TERMINATED PHASE3
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
NCT04288427 RECRUITING NA
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
NCT00945490 COMPLETED PHASE3
Kinetics of the Finasteride Prostate Induced Apoptosis
NCT00130767 UNKNOWN PHASE4
Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan
NCT01323998 COMPLETED
A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)
NCT00651807 TERMINATED PHASE2
Treatment of BPH With CO2 Serenoa +PEA as Monotherapy or in Combination With Tamsulosin: ProSeRePEA Trial
NCT06181175 RECRUITING NA